AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago ...

AbbVie on Wednesday said the replicate Phase 3 studies met their co-primary endpoints of reduction in de-pigmentation over the entire body and the face in adults and adolescents with non-segmental ...

In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial ...

AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median.

Learn more about whether AbbVie Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

As markets adjust to higher rates and uneven growth, investors are gravitating towards businesses that balance resilience ...

If I’m a little nervous, just a little nervous, I’m going to go with something that’s kind of on the safe side. AbbVie Inc ...

We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Stephanie Link picks Aptiv (APTV). Joe ...

At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...